Joel S Eppig1, Emily C Edmonds2, Laura Campbell3, Mark Sanderson-Cimino1, Lisa Delano-Wood2, Mark W Bondi2. 1. 1San Diego State University/University of California,San Diego,Joint Doctoral Program in Clinical Psychology,San Diego,California. 2. 2Department of Psychiatry,University of California San Diego,School of Medicine,La Jolla,California. 3. 3Veterans Affairs San Diego Healthcare System,San Diego,California.
Abstract
OBJECTIVES: Research demonstrates heterogeneous neuropsychological profiles among individuals with mild cognitive impairment (MCI). However, few studies have included visuoconstructional ability or used latent mixture modeling to statistically identify MCI subtypes. Therefore, we examined whether unique neuropsychological MCI profiles could be ascertained using latent profile analysis (LPA), and subsequently investigated cerebrospinal fluid (CSF) biomarkers, genotype, and longitudinal clinical outcomes between the empirically derived classes. METHODS: A total of 806 participants diagnosed by means of the Alzheimer's Disease Neuroimaging Initiative (ADNI) MCI criteria received a comprehensive neuropsychological battery assessing visuoconstructional ability, language, attention/executive function, and episodic memory. Test scores were adjusted for demographic characteristics using standardized regression coefficients based on "robust" normal control performance (n=260). Calculated Z-scores were subsequently used in the LPA, and CSF-derived biomarkers, genotype, and longitudinal clinical outcome were evaluated between the LPA-derived MCI classes. RESULTS: Statistical fit indices suggested a 3-class model was the optimal LPA solution. The three-class LPA consisted of a mixed impairment MCI class (n=106), an amnestic MCI class (n=455), and an LPA-derived normal class (n=245). Additionally, the amnestic and mixed classes were more likely to be apolipoprotein e4+ and have worse Alzheimer's disease CSF biomarkers than LPA-derived normal subjects. CONCLUSIONS: Our study supports significant heterogeneity in MCI neuropsychological profiles using LPA and extends prior work (Edmonds et al., 2015) by demonstrating a lower rate of progression in the approximately one-third of ADNI MCI individuals who may represent "false-positive" diagnoses. Our results underscore the importance of using sensitive, actuarial methods for diagnosing MCI, as current diagnostic methods may be over-inclusive. (JINS, 2017, 23, 564-576).
OBJECTIVES: Research demonstrates heterogeneous neuropsychological profiles among individuals with mild cognitive impairment (MCI). However, few studies have included visuoconstructional ability or used latent mixture modeling to statistically identify MCI subtypes. Therefore, we examined whether unique neuropsychological MCI profiles could be ascertained using latent profile analysis (LPA), and subsequently investigated cerebrospinal fluid (CSF) biomarkers, genotype, and longitudinal clinical outcomes between the empirically derived classes. METHODS: A total of 806 participants diagnosed by means of the Alzheimer's Disease Neuroimaging Initiative (ADNI) MCI criteria received a comprehensive neuropsychological battery assessing visuoconstructional ability, language, attention/executive function, and episodic memory. Test scores were adjusted for demographic characteristics using standardized regression coefficients based on "robust" normal control performance (n=260). Calculated Z-scores were subsequently used in the LPA, and CSF-derived biomarkers, genotype, and longitudinal clinical outcome were evaluated between the LPA-derived MCI classes. RESULTS: Statistical fit indices suggested a 3-class model was the optimal LPA solution. The three-class LPA consisted of a mixed impairment MCI class (n=106), an amnestic MCI class (n=455), and an LPA-derived normal class (n=245). Additionally, the amnestic and mixed classes were more likely to be apolipoprotein e4+ and have worse Alzheimer's disease CSF biomarkers than LPA-derived normal subjects. CONCLUSIONS: Our study supports significant heterogeneity in MCI neuropsychological profiles using LPA and extends prior work (Edmonds et al., 2015) by demonstrating a lower rate of progression in the approximately one-third of ADNI MCI individuals who may represent "false-positive" diagnoses. Our results underscore the importance of using sensitive, actuarial methods for diagnosing MCI, as current diagnostic methods may be over-inclusive. (JINS, 2017, 23, 564-576).
Authors: Paul S Aisen; Ronald C Petersen; Michael C Donohue; Anthony Gamst; Rema Raman; Ronald G Thomas; Sarah Walter; John Q Trojanowski; Leslie M Shaw; Laurel A Beckett; Clifford R Jack; William Jagust; Arthur W Toga; Andrew J Saykin; John C Morris; Robert C Green; Michael W Weiner Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: Emily C Edmonds; Lisa Delano-Wood; Lindsay R Clark; Amy J Jak; Daniel A Nation; Carrie R McDonald; David J Libon; Rhoda Au; Douglas Galasko; David P Salmon; Mark W Bondi Journal: Alzheimers Dement Date: 2014-05-22 Impact factor: 21.566
Authors: David J Libon; Deborah A G Drabick; Tania Giovannetti; Catherine C Price; Mark W Bondi; Joel Eppig; Kathryn Devlin; Christine Nieves; Melissa Lamar; Lisa Delano-Wood; Daniel A Nation; Laura Brennan; Rhoda Au; Rod Swenson Journal: J Alzheimers Dis Date: 2014 Impact factor: 4.472
Authors: Tanis J Ferman; Glenn E Smith; Kejal Kantarci; Bradley F Boeve; V Shane Pankratz; Dennis W Dickson; Neill R Graff-Radford; Zbigniew Wszolek; Jay Van Gerpen; Ryan Uitti; Otto Pedraza; Melissa E Murray; Jeremiah Aakre; Joseph Parisi; David S Knopman; Ronald C Petersen Journal: Neurology Date: 2013-11-08 Impact factor: 9.910
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Li Shen; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2013-08-07 Impact factor: 21.566
Authors: Emily C Edmonds; Joel Eppig; Mark W Bondi; Kelly M Leyden; Bailey Goodwin; Lisa Delano-Wood; Carrie R McDonald Journal: Neurology Date: 2016-10-19 Impact factor: 9.910
Authors: Ali Ezzati; Andrea R Zammit; Christian Habeck; Charles B Hall; Richard B Lipton Journal: Brain Imaging Behav Date: 2020-10 Impact factor: 3.978
Authors: Emily C Edmonds; Alexandra J Weigand; Kelsey R Thomas; Joel Eppig; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Mark W Bondi Journal: J Int Neuropsychol Soc Date: 2018-09 Impact factor: 2.892
Authors: Alessandro A Jammal; Nara G Ogata; Fábio B Daga; Ricardo Y Abe; Vital P Costa; Felipe A Medeiros Journal: Am J Ophthalmol Date: 2018-09-17 Impact factor: 5.258
Authors: Emily C Edmonds; Carrie R McDonald; Anisa Marshall; Kelsey R Thomas; Joel Eppig; Alexandra J Weigand; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Mark W Bondi Journal: Alzheimers Dement Date: 2019-02-06 Impact factor: 21.566
Authors: Kelsey R Thomas; Joel S Eppig; Alexandra J Weigand; Emily C Edmonds; Christina G Wong; Amy J Jak; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Steven D Edland; Mark W Bondi Journal: Alzheimers Dement Date: 2019-01-11 Impact factor: 21.566
Authors: Andrea R Zammit; Charles B Hall; Mindy J Katz; Graciela Muniz-Terrera; Ali Ezzati; David A Bennett; Richard B Lipton Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Kelsey R Thomas; Emily C Edmonds; Joel S Eppig; Christina G Wong; Alexandra J Weigand; Katherine J Bangen; Amy J Jak; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Steven D Edland; Mark W Bondi Journal: Alzheimers Dement Date: 2019-09-05 Impact factor: 21.566
Authors: Andrea R Zammit; David A Bennett; Charles B Hall; Richard B Lipton; Mindy J Katz; Graciela Muniz-Terrera Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472